Rekombinanter OLIG2 Antikörper (AA 200-300)
Kurzübersicht für Rekombinanter OLIG2 Antikörper (AA 200-300) (ABIN7871943)
Target
Alle OLIG2 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 200-300
-
Verwendungszweck
- OLIG2 Antibody
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 200-300) from the human protein was used as the immunogen for the OLIG2 antibody.
-
Isotyp
- IgG, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the OLIG2 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the OLIG2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- OLIG2 (Oligodendrocyte Lineage Transcription Factor 2 (OLIG2))
-
Andere Bezeichnung
- OLIG2
-
Hintergrund
- Olig2, a basic helix-loop-helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue.
-
UniProt
- Q13516
Target
-